Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#3770 Molecular imaging, molecular profiling and outcomes in patients with transformation to grade 3 neuroendocrine neoplasia (NEN)

Introduction: Transformation of Grade (G) 1-2 to G3 NEN has prognostic & therapeutic implications, but its mechanisms are unclear.

Conference:

Presenting Author: Kong G

Authors: Kong G, Prall O, Flynn A, Tothill R, Hatzimihalis A,

Keywords: G3, transformation, IHC, genomic sequencing, FDG PET/CT, P53, Rb1, mutations,

#3720 Efficacy of somatostatin analogues (SSA) in G3 neuroendocrine neoplasms – A comprehensive analysis among the SwissNET cohort

Introduction: G3 differentiated neuroendocrine neoplasms (NEN) are divided into G3 NET and NEC depending on their histological appearance and proliferation index. The literature on different systemic treatment options in these G3 entities is scarce especially for use of somatostatin analogues (SSA).

Conference:

Presenting Author: Siebenhüner A

Authors: Siebenhüner A, Christ E, Kollar A,

Keywords: neuroendocrine neoplasm, neuroendocrine tumor G3, neuroendocrine carcinoma G3, registry, somatostatin analogues, survival,

#3610 C-X-C receptor 4 (CXCR4)-directed imaging and therapy in NEN patients with varying tumor aggressiveness – Diagnostic performance and eligibility for CXCR4-targeted theragnostics

Introduction: C-X-C motif chemokine receptor 4 (CXCR4) has emerged as a promising target in neuroendocrine neoplasms (NEN).

Conference:

Presenting Author: Weich A

Authors: Weich A, Schlötelburg W, Hartrampf P, Serfling S, Heinrich M,

Keywords: CXCR4, radioligand therapy, PET, theragnostics, imaging,

#3565 Grade 3 neuroendocrine neoplasms – Real life experience and prognostic biomarkers

Introduction: Grade 3 neuroendocrine neoplasms (G3 NEN) are a heterogeneous group, including well differentiated tumors (NET) and poorly differentiated carcinomas (NEC), whose identification can be challenging. Accessible prognostic tools are needed to individualize treatment. Data suggests neutrophil/lymphocyte ratios (NLR) and systemic inflammatory index (SII) have prognostic value in NEN.

Conference:

Presenting Author: Rebordão Pires M

Authors: Rebordão Pires M, Monteiro J, Amorim Costa C, Caetano A, Elvas A,

Keywords: Grade 3 neuroendocrine neoplasm, NEC, NET, Neutrophil to lymphocyte ratio, Systemic Inflammatory Index, Ki67, Prognostic biomarker,

#3523 NICENEC phase 2 trial of nivolumab and platinum-doublet chemotherapy in untreated advanced G3 Neuroendocrine Neoplasms (NENs) of gastroenteropancreatic (GEP) or unknown (UK) origin: Efficacy by differentiation, KI67 index and primary tumor site

Introduction: G3 NENs are aggressive tumors with limited treatment options. Prognosis is rather poor even with best available platinum-based CT (OS of 11m).

Conference:

Presenting Author:

Authors: Riesco-Martinez M, Capdevila J, Alonso V, Jimenez-Fonseca P, Teulé A,

Keywords: Grade 3 Neuroendocrine Neoplasm, nivolumab, gastroenteropancreatic,